The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen

International Journal of Radiation Oncology, Biology, Physics
J J WuM S Anscher

Abstract

To determine the efficacy of radiotherapy (RT) in patients with an isolated elevation of prostate specific antigen (PSA) after radical prostatectomy (RP). Between November 1987 and May 1993, 53 patients with adenocarcinoma of the prostate were referred for pelvic RT for an elevated PSA after RP. No patient had clinically or radiographically apparent local or distant disease, nor had an undergone prior androgen ablation. Patients received a median dose of 61.2 Gy to the prostatic bed. An undetectable PSA was required to be considered disease free (NED). Univariate and multivariate analyses were performed to identify factors predictive of becoming disease free after RT. The median follow-up was 15 months. Of the 53 patients, 16 (30%) became NED after RT and 15 (28%) had a declining (n = 11) or stable (n = 4) PSA at last evaluation. The median time after RT to achieve an undetectable PSA was 9.3 months. At 12 and 24 months, the actuarial disease-free survival was 30 and 23%, respectively; actuarial progression-free survival was 71 and 26%, respectively. By univariate analysis, the last PSA level before RT (i.e., the pre-RT PSA) and an undetectable PSA after RP were significant predictors of becoming NED (p = 0.0001 and 0.04, respe...Continue Reading

References

Oct 1, 1990·The Journal of Urology·D J LightnerL Moore
Dec 1, 1990·International Journal of Radiation Oncology, Biology, Physics·M E KeischW Catalona
Sep 1, 1991·International Journal of Radiation Oncology, Biology, Physics·M S Anscher, L R Prosnitz
Oct 8, 1987·The New England Journal of Medicine·T A StameyE Redwine
Aug 30, 1995·International Journal of Radiation Oncology, Biology, Physics·M S AnscherR Prosnitz

❮ Previous
Next ❯

Citations

Feb 17, 2001·International Journal of Cancer. Journal International Du Cancer·R R Allison, A Schulsinger
Oct 18, 2005·Der Urologe. Ausg. A·M P WirthM Fröhner
Mar 3, 2007·World Journal of Urology·Manfred P WirthMichael Froehner
Jun 27, 2002·Current Urology Reports·C R Pound, A W Partin
Feb 1, 1996·International Journal of Radiation Oncology, Biology, Physics·M S Anscher
Feb 19, 2004·Urologic Oncology·Jordan MaierJ Edson Pontes
May 7, 2002·Urology·Ramona MayerArnulf Hackl
Feb 23, 1999·The Urologic Clinics of North America·D K OrnsteinG L Andriole
Oct 10, 2001·The Urologic Clinics of North America·S E Schild, T M Pisansky
Sep 10, 2003·Current Problems in Cancer·Judd W Moul
Apr 11, 2001·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·C CattonM Milosevic
Nov 3, 2001·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·C ParkerC Catton
Sep 7, 2000·International Journal of Radiation Oncology, Biology, Physics·M S AnscherR Dodge
May 23, 2002·International Journal of Radiation Oncology, Biology, Physics·Richard ChooGerrit DeBoer
Jun 6, 2003·International Journal of Radiation Oncology, Biology, Physics·N TaylorA Pollack
Oct 6, 1997·International Journal of Radiation Oncology, Biology, Physics·M J ZelefskyS A Leibel
Oct 23, 1997·International Journal of Radiation Oncology, Biology, Physics·C H CraneM D Kelly
Nov 7, 1998·International Journal of Radiation Oncology, Biology, Physics·R K ValicentiB W Corn
Feb 14, 2006·Nature Clinical Practice. Urology·Andrew J Stephenson, Kevin M Slawin
Jun 8, 2001·Mayo Clinic Proceedings·J A Wieder, A S Belldegrun
Sep 22, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jennifer L PetersonThomas M Pisansky
Apr 29, 1998·Seminars in Radiation Oncology·S E Schild
May 8, 2000·The Journal of Urology·J W Moul
Jun 7, 2000·The Journal of Urology·G D GrossfeldP R Carroll
Nov 1, 1996·The Urologic Clinics of North America·S B Malkowicz
Nov 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shelly Bowers Hayes, Alan Pollack
Mar 15, 2006·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·M BossetP Maingon

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.